Interpace Biosciences, Inc. Sustainability Profile
Interpace Biosciences, Inc., a leading player in the biotechnology sector, is headquartered in the United States, with significant operations across various regions. Founded in 2008, the company has established itself as a pioneer in molecular diagnostics and personalised medicine, focusing on innovative solutions for cancer detection and management. Interpace offers a range of unique products and services, including its proprietary tests that aid in the diagnosis and treatment of thyroid and other cancers. These offerings are distinguished by their ability to provide actionable insights, enhancing patient care and clinical decision-making. With a strong market position, Interpace has achieved notable milestones, including partnerships with healthcare providers and advancements in genomic testing technologies, solidifying its reputation as a trusted resource in the evolving landscape of precision medicine.
DitchCarbon Score
How does Interpace Biosciences, Inc.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Business Services industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Interpace Biosciences, Inc.'s score of 23 is lower than 68% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Interpace Biosciences, Inc.'s reported carbon emissions
Interpace Biosciences, Inc., headquartered in the US, currently does not have available carbon emissions data for the most recent year. As a result, there are no specific figures regarding their total emissions or breakdowns by Scope 1, Scope 2, or Scope 3. Furthermore, the company has not established any documented reduction targets or commitments to climate initiatives, such as those outlined by the Science Based Targets initiative (SBTi) or other industry standards. Given the absence of emissions data and reduction initiatives, it is unclear how Interpace Biosciences is addressing climate change or its carbon footprint. The company may need to develop and communicate its climate commitments to align with industry best practices and stakeholder expectations.
How Carbon Intensive is Interpace Biosciences, Inc.'s Industry?
How Carbon Intensive is Interpace Biosciences, Inc.'s Location?
Interpace Biosciences, Inc.'s Climate Goals (2030 & 2050)
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Interpace Biosciences, Inc. has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
Let us know if this data was useful to you
Usage Policy
You're welcome to quote or reference data from this page, but please include a visible link back to this URL.
Bulk collection, resale, or redistribution of data from multiple profiles is not permitted.
See our License Agreement for more details.